AERI - アエリ―・ファ―マシュ―ティカルズ (Aerie Pharmaceuticals Inc.) アエリ―・ファ―マシュ―ティカルズ

 AERIのチャート


 AERIの企業情報

symbol AERI
会社名 Aerie Pharmaceuticals Inc (アエリ―・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アエリー・ファーマシューティカル(Aerie Pharmaceuticals Inc.)は臨床病期の製薬会社である。同社は緑内障及び眼の他の疾患の患者のための治療法の発見・開発・商業化に従事する。同社の製品候補には、Rhopressa(netarsudil点眼液)0.02%(Rhopressa)、Roclatan(netarsudil /ラタノプロスト点眼液)0.02%/ 0.005%(Roclatan)が含まれる。同社の製品候補は、開放隅角緑内障および高眼圧症患者の眼内圧(IOP)を下げるように設計される。そのRhopressaは1日1回の点眼薬である。Rhopressaは、IOPを低下させる生化学的標的であるRhoキナーゼ(ROCK)およびノルエピネフリントランスポーター(NET)を阻害する。そのRoclatanは、オープンアングルの緑内障患者の治療薬として処方されているRhopressaとlatanoprostの1日1回、固定用量の組み合わせである。同社はRoclatanの第III相臨床試験を実施している。   アエリ―・ファ―マシュ―ティカルズは米国の製薬会社。緑内障とその他目の疾患治療薬の発見、開発、商業化を行う。緑内障と高眼圧症向けに一日一回投薬で眼圧を下げるRhoキナ―ゼ阻害剤「ロ―プレッサ」と「ロクラタン」の第3相治験を行う。また、第2世代のRhoキナ―ゼ阻害剤が臨床前段階。本社はカリフォルニア州。   Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
本社所在地 4301 Emperor Boulevard Suite 400 Durham CA 27703 USA
代表者氏名 Vicente Anido ヴィセンテ・アニード
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 919-313-9650
設立年月日 38504
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 160人
url www.aeriepharma.com
nasdaq_url https://www.nasdaq.com/symbol/aeri
adr_tso
EBITDA EBITDA(百万ドル) -187.08400
終値(lastsale) 54.17
時価総額(marketcap) 2449689445.01
時価総額 時価総額(百万ドル) 2406.276
売上高 売上高(百万ドル) 2.42300
企業価値(EV) 企業価値(EV)(百万ドル) 2244.172
当期純利益 当期純利益(百万ドル) -186.60800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aerie Pharmaceuticals Inc revenues increased from $0K to $2.4M. Net loss increased 77% to $95.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase from $22.6M to $53.3M (expense) Research and development - Other increase of 39% to $26.5M (expense).

 AERIのテクニカル分析


 AERIのニュース

   Aerie Pharmaceuticals Q2 2022 Earnings Preview (NASDAQ:AERI)  2022/08/03 21:35:34 Seeking Alpha
Aerie Pharmaceuticals (AERI) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.The consensus EPS Estimate is -$0.55 (compared to -$0.83 in year…
   Aerie Pharma PT Lowered to $12 at Truist Securities  2022/08/01 11:22:21 Investing.com
https://www.investing.com/news/pro/aerie-pharma-pt-lowered-to-12-at-truist-securities-432SI-2859306
   Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET - Stocks News Feed  2022/07/29 01:10:00 Stocks News Feed
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m.… Read More »Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
   Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5: 00 p.m. ET  2022/07/28 22:10:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to
   Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Is Currently -102.47 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential.  2022/07/09 17:00:00 Marketing Sentinel
Aerie Pharmaceuticals Inc. (NASDAQ:AERI)’s traded shares stood at 0.54 million during the last session, with the company’s beta value hitting 0.43. At the close of trading, the stock’s price was $8.50, to imply a decrease of -0.93% or -$0.08 in intraday trading. The AERI share’s 52-week high remains $17.21, putting it -102.47% down since that … Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Is Currently -102.47 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. Read More »
   Rate - Stock Analysts'' Downgrades for June 20th (AERI, AIZ, CMC, CMRE, COLM, CPS, DLA, FFIN, HCSG, HTGC)  2022/06/21 03:51:09 Business Mag
Stock Analysts'' downgrades for Monday, June 20th: Aerie Pharmaceuticals was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Assurant was downgraded…
   Aerie Pharmaceuticals Q2 2022 Earnings Preview  2022/06/09 21:35:13 Seeking Alpha
Aerie Pharmaceuticals (AERI) is scheduled to announce Q2 earnings results on Friday, June 10th, after market close.The consensus EPS Estimate is -$0.55 (+33.7% Y/Y) and the…
   Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET  2022/05/25 20:30:00 Kwhen Finance
   Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study  2022/05/24 20:15:38 Benzinga
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). This study is the first of three trials in the Phase 3 registrational program for AR-15512. Aerie Pharmaceuticals is … Full story available on Benzinga.com
   Aerie Pharmaceuticals begins dosing in late-stage study of AR-15512 for dry eye disease  2022/05/24 18:12:58 Seeking Alpha
Aerie Pharmaceuticals (AERI) said the first person was dosed in a phase 3 trial of AR-15512 ophthalmic solution to treat the signs and symptoms of dry eye disease.The company added…
   Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)  2021/12/22 21:01:00 Kwhen Finance
   Aerie Pharmaceuticals (NASDAQ:AERI) Receives New Coverage from Analysts at Needham & Company LLC  2021/12/18 11:22:42 Transcript Daily
Needham & Company LLC started coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research note released on Friday morning, TipRanks reports. The firm issued a buy rating and a $22.00 price target on the stock. Several other research firms have also issued reports on AERI. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from []
   Aerie Pharmaceuticals Inc. (NASDAQ: AERI): Would You Buy Today?  2021/12/14 13:00:00 Marketing Sentinel
In the last trading session, 2.33 million shares of the Aerie Pharmaceuticals Inc. (NASDAQ:AERI) were traded, and its beta was 0.84. Most recently the company’s share price was $8.75, and it changed around -$0.24 or -2.67% from the last close, which brings the market valuation of the company to $420.00M. AERI currently trades at a … Aerie Pharmaceuticals Inc. (NASDAQ: AERI): Would You Buy Today? Read More »
   Aerie Pharmaceuticals Inc. (NASDAQ: AERI): Stock Plunge On The Way?  2021/12/13 15:00:00 Stocks Register
The trading price of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) closed lower on Friday, December 10, closing at $8.99, -2.92% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
   Aerie Pharmaceuticals (NASDAQ:AERI) Stock Price Crosses Below 200-Day Moving Average of $14.06  2021/12/11 07:58:43 ETF Daily News
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.06 and traded as low as $8.98. Aerie Pharmaceuticals shares last traded at $8.99, with a volume of 1,292,072 shares traded. Several analysts recently issued reports on AERI shares. HC [] The post Aerie Pharmaceuticals (NASDAQ:AERI) Stock Price Crosses Below 200-Day Moving Average of $14.06 appeared first on ETF Daily News .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アエリ―・ファ―マシュ―ティカルズ AERI Aerie Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)